目的 探讨积雪苷片联合曲尼司特治疗瘢痕疙瘩的临床疗效。方法 选取2015年1月—2017年1月在河南省职工医院诊治的瘢痕疙瘩患者66例，随机分为对照组（33例）和治疗组（33例）。对照组口服曲尼司特胶囊，0.1 g/次，3次/d。治疗组在对照组的基础上口服积雪苷片，0.2 g/次，2次/d。两组均经过8周治疗。观察两组患者临床疗效，比较治疗前后两组患者温哥华瘢痕量表（VSS）、视觉模拟评分（VAS）、焦虑自评量表（SAS）、抑郁自评量表（SDS）和QLQ-C30评分及瘢痕厚度和瘢痕面积。结果 治疗后，对照组和治疗组临床总有效率分别为72.73%、93.94%，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组VSS评分、VAS评分、SAS评分和SDS评分均显著降低（P < 0.05）；且治疗组上述评分均低于对照组（P < 0.05）。治疗后，两组瘢痕厚度和瘢痕面积均明显减小（P < 0.05）；且治疗组比对照组减小更显著（P < 0.05）。治疗后，两组QLQ-C30功能领域评分均明显增高（P < 0.05）；且治疗组比对照组增高更显著（P < 0.05）。结论 积雪苷片联合曲尼司特治疗瘢痕疙瘩有利于改善患者临床症状，提高患者生活质量，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Jixuegan Tablets combined with tranilast in treatment of keloid. Methods Patients (66 cases) with keloid in Henan Staff Hospital from January 2015 to January 2017 were randomly divided into control (33 cases) and treatment (33 cases) groups. Patients in the control group were po administered with Tranilast Capsules, 0.1 g/time, three times daily. Patients in the treatment group were po administered with Jixuegan Tablets on the basis of the control group, 0.2 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the VSS, VAS, SAS, SDS and QLQ-C30 scores, scar thickness and scar area in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 72.73% and 93.94%, respectively, and there were differences between two groups (P < 0.05). After treatment, the VSS, VAS, SAS and SDS scores in two groups were significantly decreased (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the scar thickness and scar area in two groups was significantly reduced (P < 0.05), and the scar thickness and scar area in the treatment group were significantly smaller than that in the control group (P < 0.05). After treatment, the QLQ-C30 scores in two groups were significantly increased (P < 0.05), and the QLQ-C30 scores in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion Jixuegan Tablets combined with tranilast in treatment of keloid can improve the clinical symptoms and the quality of life, which has a certain clinical application value.